BOTHELL, Wash.--(BUSINESS WIRE)--Helix BioMedix, Inc. (OTCBB:HXBM), a developer of bioactive peptides, today announced that it has retained the Shelton Group to serve as its strategic investor relations counsel.
Shelton Group is a full service corporate communications agency offering integrated programs for both investor relations and public relations to leading public companies across multiple industries. With more than 13 years of experience, Shelton Group’s Investor Relations team provides all aspects of strategic counsel designed to raise the visibility of client companies as well as to build and sustain investor support.
